样式: 排序: IF: - GO 导出 标记为已读
-
Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-18 Yu Cheng, Yujia Zhang, Ying Zhang, Maobai Liu, Limei Zhao
-
Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-18 Mohammad Tanashat, Almothana Manasrah, Mohamed Abouzid
-
Pharmacokinetics of polymyxin B in different populations: a systematic review Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-14 Xing Wang, Wenqiang Xiong, Maolian Zhong, Yan Liu, Yuqing Xiong, Xiaoyi Yi, Xiaosong Wang, Hong Zhang
-
Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-14 Zhipeng Wang, Hongsen Wang, Chen Bu, Bosu Meng, Yuhui Mu, Shouhong Gao, Wansheng Chen, Xia Tao
-
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-13 Mustafa Korkmaz, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem, Aykut Demirkıran, Murat Araz, Mehmet Artaç
-
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-12 Fabian Kerwagen, Christoph Ohlmeier, Thomas Evers, Stefan Herrmann, Inga Bayh, Alexander Michel, Silvia Kruppert, Joanna Wilfer, Rolf Wachter, Michael Böhm, Stefan Störk
-
Activities of clinical pharmacologists across Europe: A survey by the European association of clinical pharmacology and therapeutics Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-11 Pierre Marquet, Emilie Jouanjus, Joaquin Sáez-Peñataro, Aranzazu Sancho-Lopez
-
Incidence, characteristics, and risk factors of drug-associated muscle adverse reaction: a retrospective real-world study of inpatients Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-05 Anqi Zhao, Daihong Guo, Man Zhu, Ao Gao, Peng Li, An Fu
-
Impact of combined propranolol and oxytocin on the process and outcomes of labor: a meta-analysis of randomized controlled trials Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-04 Xia Liu, Hai-Xu Chen, Bo Chen
-
Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-02 Maaike M. E. Diesveld, Daniëlle W. M. Jacobs- Pijnenburg, Rianne A. Weersink, Ina Barzel, Joost P. H. Drenth, Ton Lisman, Herold J. Metselaar, Margje H. Monster-Simons, Midas B. Mulder, Eline Okel, Katja Taxis, Sander D. Borgsteede
-
Evaluation of methods measuring medication adherence in patients with polypharmacy: a longitudinal and patient perspective Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-03-01 Laura Mortelmans, Eva Goossens, Marjan De Graef, Jana Van Dingenen, Anne-Marie De Cock, Mirko Petrovic, Patricia van den Bemt, Tinne Dilles
-
The effects of drug-drug interaction on linezolid pharmacokinetics: A systematic review Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-29 Qiang Xu, Yanlei Sang, Anna Gao, Lu Li
-
The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-29 Sireen Abdul Rahim Shilbayeh, Iman Sharaf Adeen, Ayman Shawqi Alhazmi, Haya Aljurayb, Rana Saad Altokhais, Nourah Alhowaish, Khawlah Essa Aldilaijan, Mostafa Kamal, Anwar Mansour Alnakhli
-
Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-28
Abstract Purpose To examine the associations between use of statins and risks of various ovarian, uterine, and cervical diseases, including ovarian cancer, endometrial cancer, cervical cancer, ovarian cyst, polycystic ovarian syndrome, endometriosis, endometrial hyperplasia, endometrial polyp, and cervical polyp. Methods We conducted a cohort study among female participants in the UK Biobank. Information
-
Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients? Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-23 Onur Turan, Nalan Ogan, Fulsen Bozkus, Nurhan Sarıoğlu, Pakize Ayşe Turan, Celal Satıcı
-
Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-23 Kristine Hole, Silje K Lorentsen, Karoline L Nordby, Marie Slettvik, Ida TG Sørum, Espen Molden, Tore Haslemo
-
DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome — A 3-month, multicenter, randomized controlled clinical trial Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-22
Abstract Background The recent discovery of new therapeutic approaches to heart failure with reduced ejection fraction (HFrEF), including sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as well as improved treatment of co-morbidities has provided much needed help to HFrEF. In addition, dapagliflozin, one of the SGLT-2 inhibitors, serves as a promising candidate in treating obstructive sleep apnea
-
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-19 Clara Oliveira, Beatrice Mainoli, Gonçalo S. Duarte, Tiago Machado, Rita G. Tinoco, Miguel Esperança-Martins, Joaquim J. Ferreira, João Costa
-
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-17 Manmeet Kaur, Saurav Misra
-
Exploratory associations of tacrolimus exposure and clinical outcomes after lung transplantation: A retrospective, single center experience Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-16 Wenwen Du, Xiaoxing Wang, Dan Zhang, Xianbo Zuo
-
Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-16 Tolga Onuk, Fuat Polat, Barış Yaylak, Şükrü Akyüz, Zeynep Kolak, Furkan Durak
-
ChatGPT for generating multiple-choice questions: Evidence on the use of artificial intelligence in automatic item generation for a rational pharmacotherapy exam Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-14 Yavuz Selim Kıyak, Özlem Coşkun, Işıl İrem Budakoğlu, Canan Uluoğlu
Purpose Artificial intelligence, specifically large language models such as ChatGPT, offers valuable potential benefits in question (item) writing. This study aimed to determine the feasibility of generating case-based multiple-choice questions using ChatGPT in terms of item difficulty and discrimination levels. Methods This study involved 99 fourth-year medical students who participated in a rational
-
The effect of statins on falls and physical activity in people aged 65 and older: A systematic review Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-14 Emily Densham, Elaney Youssef, Oscar Ferguson, Rebecca Winter
-
ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-14 Boel Nilsson, Johan Bylund, Magnus M. Halldin, Matthias Rother, Erik Rein-Hedin, Kristin Önnestam, Märta Segerdahl
-
Serum trough concentration threshold and risk factors of cefoperazone-induced coagulopathy in critically ill patients: A retrospective case-control study Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-14 Qian Wang, Pei Liang, Ying Xu, Binbin Yuan, Chen Lan, Xiaodi Yan, Li Li
-
The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-12 Mohammad Amin Habibi, Mohammad Sina Mirjani, Muhammad Hussain Ahmadvand, Pouria Delbari, Omid Alasti
-
Understanding hemoglobin contribution to high-dose methotrexate disposition—population pharmacokinetics in pediatric patients with hematological malignancies Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-12 Biljana Škorić, Marija Jovanović, Miloš Kuzmanović, Branislava Miljković, Katarina Vučićević
-
COVID-19 and pregnancy: A European study on pre- and post-infection medication use Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-12
Abstract Purpose The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location. Methods We conducted an observational study using six electronic healthcare databases from six European regions
-
Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-11 Sining Zhao, Yiwu Qiu, Meiqin Yuan, Zeng Wang
Background Patients with HER2-positive cancers often face a poor prognosis, and treatment regimens containing anti-HER2 have become the first-line treatment options for breast and gastric cancers. However, these approaches are faced with significant challenges in terms of drug resistance. Hence, it is crucial to explore precise treatment strategies aimed at improving survival outcomes. Advancements
-
Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-08
Abstract Purpose To establish the population pharmacokinetics (PPK) model of cyclosporine A(CsA) in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation (HSCT), aiming at providing a reference for clinical dose individualization of CsA. Methods Children with thalassemia who underwent allogeneic HSCT were enrolled retrospectively. The PPK structural model
-
Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-06 Dabei Cai, Qianwen Chen, Lipeng Mao, Tingting Xiao, Yu Wang, Qingqing Gu, Qingjie Wang, Yuan Ji, Ling Sun
-
Comparing AGS Beers 2019, STOPP version 2, and EU(7)-PIM list in Portuguese older adults in primary health care Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-06 Daniela A. Rodrigues, Maria Teresa Herdeiro, Ramona Mateos-Campos, Adolfo Figueiras, Fátima Roque
-
Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-02-01 Zhuchen Yu, Fei Xu, Juntao Zou
-
Estimating the impact of label design on reducing the risk of medication errors by applying HEART in drug administration Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-29 Carlos Aceves-Gonzalez, Angela Caro-Rojas, John A. Rey-Galindo, Luz Aristizabal-Ruiz, Karen Hernández-Cruz
-
Association of the predicted free blood concentration of teicoplanin with the development of renal dysfunction Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-29 Kyohei Sugiyama, Keita Hirai, Yukako Suyama, Kento Furuya, Kenta Ito
-
Dabigatran-related serious medication errors: an analysis using data from VigiBase Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-29 Qingxia Zhang, Qian Ding, Qun-Ying Yue
Objective To analyze the serious medication errors (MEs) on dabigatran, and their related factors, in order to avoid or reduce the occurrence of adverse events. Methods Serious MEs related to dabigatran were extracted from the WHO global database of reported potential side effects of medicinal products (VigiBase) by using “Medication errors and other product use errors and issues” High Level Group
-
The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-25
Abstract Objectives We aimed to evaluate the relationship between use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) and incidence of various respiratory and infectious diseases and site-specific fractures. Methods Large randomized controlled trials (RCTs) of SGLT2is enrolling more than 400 subjects were included. Outcomes of interest were various serious adverse events regarding to respiratory
-
Patterns of inappropriate prescribing and clinical characteristics in patients at admission to an acute care of the elderly unit Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-24 Mónica Zuleta, Antonio San-José, Inés Gozalo, Margarita Sánchez-Arcilla, Gabriela Carrizo, Marcelo Alvarado, Carmen Pérez-Bocanegra
Purpose Inappropriate prescribing (IP) is common among the elderly and is associated with adverse health outcomes. The role of different patterns of IP in clinical practice remains unclear. The aim of this study is to analyse the characteristics of different patterns of IP in hospitalized older adults. Methods This is a prospective observational study conducted in the acute care of elderly (ACE) unit
-
Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-23 Wania Ahmer, Sahar Imtiaz, Daniyal Muhammad Alam, Khadija Ahmed, Barka Sajid, Juvairia Yousuf, Sunny Asnani, Muhammad Ahmed Ali Fahim, Rahmeen Ali, Marium Mansoor, Muhammad Talha Safdar, Muhammad Umair Anjum, Muhammad Hasanain, Muhammad Omar Larik
-
Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-23 Nasr Alrabadi, Mohammed Al-Nusair, Razan Haddad, Lama Alburie, Nizar Mhaidat, Mohamad Aljarrah, Ayman Hamoudeh
Purpose Many atrial fibrillation (AF) patients use cardiovascular medications for indications other than AF. These medications can affect morbidity and mortality. We aim to investigate the characteristics of AF patients who use different medication classes and their clinical course. Methods We collected data from the prospective, multicenter registry, JoFib study. We identified classes of non-AF medications
-
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-22
Abstract Purpose A series of iterative population pharmacokinetic (PK) modeling and probability of target attainment (PTA) analyses based on emerging data supported dose selection for aztreonam-avibactam, an investigational combination antibiotic for serious Gram-negative bacterial infections. Methods Two iterations of PK models built from avibactam data in infected patients and aztreonam data in healthy
-
A comparison of the mixed and sequential use of acetaminophen and dexketoprofen in painful vaso-occlusive crises Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-21 Murat Kaçmaz, Gül İlhan
Purpose Opioids are widely used to treat painful vaso-occlusive crises (VOC) in sickle cell disease (SCD). However, due to opioids’ significant adverse effect profiles, the search for alternative therapies continues from the past to the present. The study aimed to investigate the efficacy of acetaminophen and dexketoprofen in the treatment of painful VOC. Methods This study is a single-center, prospective
-
The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-20
Abstract Introduction To introduce a drug to the market, it’s not mandatory for it to be more effective and safer than the current treatment for the same condition. Consequently, head-to-head studies between the two best treatments for the same condition are not required, and this could result in a lack of information for patients, clinicians, and decision-makers. This study aims to evaluate the presence
-
Tofacitinib for the treatment of severe rare skin diseases: a narrative review Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-17
Abstract Purpose Autoimmune bullous diseases, connective tissue diseases, and vasculitis represent a group of severe rare skin diseases. While glucocorticoids and immunosuppressive agents serve as standard treatments for these diseases, their efficacy is limited due to adverse side effects, indicating the need for alternative approaches. Biologics have been used in the management of some rare skin
-
Effects of an intraoperative intravenous Bolus Dose of Dexmedetomidine on postoperative catheter-related bladder discomfort in male patients undergoing transurethral resection of bladder tumors: a randomized, double-blind, controlled trial Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-13 Tianhua Zhang, Huiting Li, Chunnan Lin, Rui An, Wenqian Lin, Hongying Tan, Longhui Cao
-
Drug-drug interaction perpetrators of oxycodone in patients with cancer: frequency and clinical relevance Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-13 L. M. G. Hulskotte, W. Töpfer, A. K. L. Reyners, K. Taxis, F. G. A. Jansman
-
Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-12
Abstract Purpose Owing to adverse event following immunization (AEFI) related to autoimmune disorders and coronavirus disease 2019 (COVID-19) vaccines sharing common biological mechanisms, identifying the risk of AEFIs associated with COVID-19 vaccines remains a critical unmet need. We aimed to assess the potential safety signals for 16 AEFIs and explore co-reported adverse events (AEs) and drugs using
-
Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-10 Kristine Tveit, Monica Hermann, Roy M. Nilsen, Susanna M. Wallerstedt, Arvid Rongve, Espen Molden, Kristine Hole
-
Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-10
Abstract Introduction Recent studies have found that lipid levels in patients with chronic hepatitis B (CHB) may change during antiviral therapy. Objective To assess the effects of first-line nucleot(s)ide analogues (NAs) on lipid profiles in patients with CHB using network meta-analysis. Methods Seven electronic databases (PubMed, Embase, Cochrane Library, and four Chinese databases) were searched
-
Antidepressant deprescribing: State of the art and recommendations—A literature overview Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2024-01-08 Alessia Romagnoli, Andrea Zovi, Fiorenzo Santoleri, Ruggero Lasala
-
Low-dose Rivaroxaban: is it a safe alternative in Chinese older patients? Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-30 Yue Yu, Wei Yang, Wenyuan Li, Ge Gao, Dan Luo, Yue Wu, Xianming Su
-
Effects of mirabegron on brown adipose tissue and metabolism in humans: A systematic review and meta-analysis Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-30 Lili Ma, Lianqiu Xiong, Gang Huang
-
Efficacy and safety of adalimumab in pediatric patients with Crohn’s disease: A systematic review and meta-analysis Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-29
Abstract Purpose There is currently no curative treatment for childhood Crohn’s disease (CD). This meta-analysis aimed to validate the efficacy and safety of adalimumab (ADA) in pediatric patients with CD. Materials and methods We searched all relevant studies in the PubMed, Web of Science, Embase, and Cochrane Library databases. The primary outcomes were induction (≤ 12 weeks) and maintenance (up
-
Time series analysis of using the PDCA method combined with the Teach-back method to improve spontaneous reports of adverse drug reactions in a grade IIIA hospital in China Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-27 Bo Li, Li Jiang, Li Liao, Yao Chen, Zhi Xu, Ni Wu, Heping Chen, Pan Wu, Tianhu Liu
-
Proton pump inhibitors associated with an increased risk of mortality in elderly: a systematic review and meta-analysis Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-26 Hyun Jin Song, Hyun-Ju Seo, Xinyi Jiang, Nakyung Jeon, Yoon Jae Lee, In-Hyuk Ha
-
Diverse pharmacovigilance jurisdiction—The right way for global drug safety? Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-23
Abstract Purpose The purpose of this narrative review is to provide a comparison of several countries with different legislation and approaches to pharmacovigilance and to point out how these impact the number of adverse drug reactions (ADRs) that are reported to national competent authorities. Methods Legislative and statistical data regarding ADR reporting from various national competent authorities’
-
Perception of pharmacological equivalence of generics or biosimilars in healthcare professionals in Vienna Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-22
Abstract Purpose Due to constantly rising therapy costs, biosimilars and generic drugs have gained tremendous importance through recent decades. Nevertheless, the acceptance among healthcare workers regarding biosimilars and generic drugs in previously published international studies is considerably lower than the scientific data on equivalent safety and efficacy would suggest. The aim of this questionnaire-based
-
A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-20 Ya-Ting Wang, Xiao-Le Wang, Lan Lei, Zhen-Yu Guo, Fei-Fei Kan, Die Hu, Cong Gai, Yi Zhang
-
Association of antidepressants plus antithrombotics and bleeding risk: a pharmacovigilance study Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-19
Abstract Aim The present study investigated the risk of bleeding when antidepressants are added to antithrombotics. Methods Using data registered in VigiBase®, the WHO pharmacovigilance database, between 01/01/2000 and 31/12/2022, we compared the risk of reporting “serious” bleeding (Reporting Odds Ratio, ROR) with antidepressants + antithrombotics versus antithrombotics alone. Results Increased values
-
The incidence and prevalence of proton pump inhibitor usage among internal medicine patients after hospital admission: A retrospective cohort study Eur. J. Clin. Pharmacol. (IF 2.9) Pub Date : 2023-12-18 Helga Rut Steinsdóttir, Martin I. Sigurðsson, Einar Stefán Björnsson, Freyja Jónsdóttir